Supplementary Table 1. Baseline characteristics and clinical features of survivor and non-survivor group in the low APACHE-II score group (< 27.5)

| Characteristic                          | Survivor (n = 39) | Non-survivor (n = 36) | p value |
|-----------------------------------------|------------------|-----------------------|---------|
| Serum NGAL, ng/mL                       | 383.0 (215.0–713.0) | 716.0 (397.5–1,239.8) | 0.003   |
| APACHE-II score                         | 22.0 (16.0–24.0)  | 24.0 (22.0–26.0)      | 0.012   |
| SOFA score                              | 10.0 (8.0–12.0)   | 11.0 (10.0–13.0)      | 0.032   |
| Serum NGAL ≥ 511.5 ng/mL                | 13 (33.3)         | 23 (63.9)             | 0.008   |
| APACHE-II score ≥ 23.5                  | 13 (33.3)         | 21 (58.3)             | 0.030   |
| SOFA score ≥ 10.5                       | 19 (48.7)         | 23 (63.9)             | 0.186   |
| Age, yr                                 | 57.1 ± 17.1       | 64.8 ± 15.9           | 0.047   |
| Body mass index, kg/m²                  | 23.6 ± 3.9        | 22.3 ± 3.6            | 0.168   |
| Male sex                                | 24 (61.5)         | 19 (52.8)             | 0.443   |
| C-reactive protein, mg/dL               | 9.5 (2.7–18.4)    | 13.5 (8.1–18.5)       | 0.360   |
| Mechanical ventilation                  | 15 (38.5)         | 20 (55.6)             | 0.138   |
| Inotropics administration               | 18 (46.2)         | 25 (69.4)             | 0.042   |
| Indication for CRRT initiation          |                  |                       |         |
| Sepsis                                  | 13 (33.3)         | 22 (61.1)             | 0.016   |
| Postoperation                           | 7 (17.9)          | 1 (2.8)               | 0.058   |
| Cardiac                                 | 4 (10.3)          | 4 (11.1)              | 1.000   |
| Pulmonary                               | 0                 | 1 (2.8)               | 0.480   |
| Hepatic                                 | 8 (20.5)          | 3 (8.3)               | 0.136   |
| Renal                                   | 2 (5.1)           | 2 (5.6)               | 1.000   |
| Malignancy                              | 5 (12.8)          | 3 (8.3)               | 0.713   |
| Others                                  | 0                 | 0                     | -       |
| Comorbidities                           |                  |                       |         |
| Diabetes mellitus                       | 14 (35.9)         | 9 (25.0)              | 0.307   |
| Hypertension                            | 14 (35.9)         | 18 (50.0)             | 0.217   |
| Chronic kidney disease                  | 6 (15.4)          | 6 (16.7)              | 0.880   |
| Cerebro-cardiovascular disease          | 12 (30.8)         | 10 (27.8)             | 0.776   |
| Pulmonary disease                       | 1 (2.6)           | 1 (2.8)               | 1.000   |
| Liver disease                           | 12 (30.8)         | 5 (13.9)              | 0.081   |
| Dementia                                | 0                 | 1 (2.8)               | 0.480   |
| Malignancy                              | 7 (17.9)          | 12 (33.3)             | 0.126   |

Values are presented as median (interquartile range), number (%), or mean ± SD.
APACHE-II, Acute Physiology and Chronic Health Evaluation-II; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement therapy.